Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction-DOSE Finding Study) Trial

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

(2022) Michael J. Koren et al.   NATURE MEDICINE

Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels

(2022) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

(2021) Glen J. Pearson et al.   CANADIAN JOURNAL OF CARDIOLOGY

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

(2021) Gregory G. Schwartz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association

(2021) Gissette Reyes-Soffer et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

(2020) Vera A. Bittner et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

(2020) Sotirios Tsimikas et al.   NEW ENGLAND JOURNAL OF MEDICINE

EXPRESS: Lp(a): when and how to measure it

(2020) Jaimini Cegla et al.   ANNALS OF CLINICAL BIOCHEMISTRY

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

(2019) Michelle L. O'Donoghue et al.   CIRCULATION

Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group

(2019) Don P. Wilson et al.   Journal of Clinical Lipidology

Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes

(2019) Claudia Lamina et al.   JAMA Cardiology

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

HEART UK consensus statement on Lipoprotein(a): A call to action

(2019) Jaimini Cegla et al.   ATHEROSCLEROSIS

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

(2018) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies

(2018) Stephen Burgess et al.   JAMA Cardiology

Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice

(2018) Xuchu Que et al.   NATURE

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular DiseaseHighlights

(2016) Eberhard Roeseler et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology

(2016) Børge G. Nordestgaard et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease

(2013) Josef Leebmann et al.   CIRCULATION

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality

(2009)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma

(2008) Claes Bergmark et al.   JOURNAL OF LIPID RESEARCH